Briefing
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Recruiting phase 2 trial of de-escalated adjuvant and definitive radiotherapy informed by DART 2.0 circulating tumor HPV DNA, planned enrollment 455. Follow-on to the original DART trial (NCT02908477), in which ctDNA was a secondary correlative rather than the randomization factor.
- Design: Phase 2 · Recruiting